Health-Related Quality of Life (HRQoL) with Fedratinib, a Selective, Oral Inhibitor of Janus Kinase 2 (JAK2), in the Phase II JAKARTA2 Study in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib

被引：1

作者：

Harrison, Claire N. ^{[1
]}

Schaap, Nicolaas ^{[2
]}

Vannucchi, Alessandro M. ^{[3
]}

Kiladjian, Jean-Jacques ^{[4
]}

Jourdan, Eric ^{[5
]}

Silver, Richard T. ^{[6
]}

Schouten, Harry C. ^{[7
]}

Passamonti, Francesco ^{[8
]}

Zweegman, Sonja ^{[9
]}

Talpaz, Moshe ^{[10
]}

Verstovsek, Srdan ^{[11
]}

Rose, Shelonitda ^{[12
]}

Tang, Derek ^{[12
]}

Hu, Angela ^{[12
]}

Guo, Shien ^{[13
]}

Liao, Weiqin ^{[13
]}

Brownstein, Carrie ^{[14
]}

Mesa, Ruben A. ^{[15
]}

机构：

[1] Guys & St Thomas NHS Fdn Trust, Dept Clin Haematol, London, England

[2] Radboud Univ Nijmegen Med Ctr, Nijmegen, Netherlands

[3] Univ Florence, AOU Careggi, Florence, Italy

[4] Hop St Louis, Paris, France

[5] Inst Cancerol Gard, Hematol Clin, Nimes, France

[6] Weill Cornell Med Coll, New York, NY USA

[7] Univ Hosp Maastricht, Dept Internal Med Hematol, Maastricht, Netherlands

[8] Univ Insubria, Dept Med & Surg, Varese, Italy

[9] Vrije Univ Amsterdam, Amsterdam UMC, Dept Hematol, Amsterdam, Netherlands

[10] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA

[11] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[12] Celgene Corp, Summit, NJ USA

[13] Evidera, Waltham, MA USA

[14] Celgene Corp, Summit, NJ USA

[15] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-129386

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2207

引用

页数：5

共 50 条

[1] Health-Related Quality of Life (HRQoL) in Patients with Myelofibrosis Treated with Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in the Randomized, Placebo-Controlled, Phase III JAKARTA Study
Mesa, Ruben A.
Schaap, Nicolaas
Vannucchi, Alessandro M.
Kiladjian, Jean-Jacques
Passamonti, Francesco
Zweegman, Sonja
Talpaz, Moshe
Verstovsek, Srdan
Rose, Shelonitda
Tang, Derek
Hu, Angela
Brownstein, Carrie
Guo, Shien
Ye, Xiaomei
Harrison, Claire N.
BLOOD, 2019, 134
[2] Safety and Tolerability of Fedratinib (FEDR), an Oral Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate- or High-Risk Myelofibrosis (MF) Previously Treated with Ruxolitinib (RUX): Results from the Phase 3b FREEDOM Trial
Gupta, Vikas
Yacoub, Abdulraheem
Verstovsek, Srdan
Mesa, Ruben A.
Harrison, Claire N.
Barosi, Giovanni
Kiladjian, Jean-Jacques
Deeg, H. Joachim
Fazal, Salman
Foltz, Lynda
Mattison, Ryan J.
Miller, Carole B.
Parameswaran, Vinod
Gharpure, Vishwanath
Hernandez, Christopher
Wang, Tianhua
Talpaz, Moshe
BLOOD, 2021, 138
[3] Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial
Harrison, Claire N.
Schaap, Nicolaas
Vannucchi, Alessandro M.
Kiladjian, Jean-Jacques
Jourdan, Eric
Silver, Richard T.
Schouten, Harry C.
Passamonti, Francesco
Zweegman, Sonja
Talpaz, Moshe
Verstovsek, Srdan
Tang, Derek
Abraham, Pranav
Lord-Bessen, Jennifer
Rose, Shelonitda
Guo, Shien
Liao, Weiqin
Mesa, Ruben A.
HEMASPHERE, 2021, 5 (05):
[4] The Effect of Fedratinib, A Selective Inhibitor of Janus Kinase 2, on Weight and Metabolic Parameters in Patients with Intermediate- or High-risk Myelofibrosis
Tremblay, Douglas
Cavalli, Lara
Sy, Oumar
Rose, Shelonitda
Mascarenhas, John
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (07): : E463 - E466
[5] The Effect of Fedratinib, a Selective Inhibitor of Janus Kinase 2 (JAK2), on Weight and Metabolic Parameters in Patients with Intermediate (INT)- or High-risk Myelofibrosis (MF)
Tremblay, Douglas
Cavalli, Lara
Banerjee, Sibabrata Raja
Rose, Shelonitda
Mascarenhas, John
BLOOD, 2020, 136
[6] Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF): Updated Results from the Randomized, Placebo-Controlled, Phase III JAKARTA Trial
Pardanani, Animesh
Tefferi, Ayalew
Masszi, Tamas
Mishchenko, Elena
Drummond, Mark W.
Jourdan, Eric
Vannucchi, Alessandro M.
Jurgutis, Mindaugas
Ribrag, Vincent
Rambaldi, Alessandro
Koh, Liang Piu
Rose, Shelonitda
Zhang, Jun
Harrison, Claire
BLOOD, 2020, 136
[7] Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure
Harrison, Claire N.
Schaap, Nicolaas
Vannucchi, Alessandro M.
Kiladjian, Jean-Jacques
Jourdan, Eric
Silver, Richard T.
Schouten, Harry C.
Passamonti, Francesco
Zweegman, Sonja
Talpaz, Moshe
Verstovsek, Srdan
Rose, Shelonitda
Shen, Juan
Berry, Tymara
Brownstein, Carrie
Mesa, Ruben A.
AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (06) : 594 - 603
[8] Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm (MPN)-Associated Intermediate- or High-Risk Myelofibrosis (MF) Resistant or Intolerant to Ruxolitinib: An Updated Analysis of the Phase II JAKARTA2 Study
Harrison, Claire
Schaap, Nicolaas
Vannucchi, Alessandro
Kiladjian, Jean-Jacques
Jourdan, Eric
Silver, Richard
Schouten, Harry
Passamonti, Francesco
Zweegman, Sonja
Talpaz, Moshe
Verstovsek, Srdan
Gerike, Torsten
Rose, Shelonitda
Li, Mingyu
Berry, Tymara
Brownstein, Carrie
Mesa, Ruben
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S356 - S356
[9] Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts
Harrison, Claire N.
Schaap, Nicolaas
Vannucchi, Alessandro M.
Kiladjian, Jean-Jacques
Passamonti, Francesco
Zweegman, Sonja
Talpaz, Moshe
Verstovsek, Srdan
Rose, Shelonitda
Zhang, Jun
Sy, Oumar
Mesa, Ruben A.
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 198 (02) : 317 - 327
[10] Fedratinib Elicits Spleen Volume or Symptom Responses in a Majority of Patients with Intermediate- or High-Risk Myelofibrosis (MF) Treated for 6 Cycles: Results from the JAKARTA and JAKARTA2 Studies
Mesa, Ruben
Vannucchi, Alessandro
Passamonti, Francesco
Kiladjian, Jean-Jacques
Mascarenhas, John
Schaap, Nicolaas
Zweegman, Sonja
Talpaz, Moshe
Harrison, Claire
Yu, Peiwen
Ye, Xiaomei
Tang, Derek
Rose, Shelonitda
Zhang, Jun
Verstovsek, Srdan
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S328 - S328

← 1 2 3 4 5 →